Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission

对母婴垂直传播中HIV-1亚型B和F的耐药突变及系统发育分析

阅读:1

Abstract

BACKGROUND: This study aimed to describe the transmission of drug-resistant HIV-1 variants and phylogenetic characterisation of viral strains in mother-child pairs from the cities of Recife and São Luís, located in the Northeast region of Brazil, in 2007-2022. METHODS: This study included 15 mother-child pairs with confirmed vertical transmission of HIV-1. The genotyping sequences were provided by the Brazilian Ministry of Health. The analyses included descriptions of antiretroviral resistance mutation profiles of the mothers and children, subtype determination, and phylogenetic analyses. RESULTS: Seven mother-child pairs exhibited similar mutation profiles, with three showing no mutations and four displaying similar resistance mutations to the nucleoside reverse transcriptase inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) drug classes. Among four pairs, mutation similarities were observed for only one antiretroviral drug class. In the remaining four pairs, distinct mutation profiles were noted, with two children having mutations in two or three drug classes and their mothers exhibiting no or one mutation. Among the eight pairs with tests obtained within the first four years after birth, six of them had very similar mutation profiles. Among the seven pairs with exams obtained five years or more after birth, four pairs presented very different DRAM profiles. Mutations conferring resistance to efavirenz, nevirapine, lamivudine, abacavir, and didanosine were frequently observed in children and mothers. Thirteen pairs (86.6%) were identified as having HIV-1 subtype B, while two (13.3%) were identified as having HIV-1 subtype F1. CONCLUSIONS: Differences in mutation profiles and antiretroviral resistance for NRTI and NNRTI drug classes were observed in half of the mother-child pairs, emphasising the importance of individualised therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。